Akebia Therapeutics Announces Board Changes and Executive Compensation
Ticker: AKBA · Form: 8-K · Filed: Mar 15, 2024 · CIK: 1517022
| Field | Detail |
|---|---|
| Company | Akebia Therapeutics, Inc. (AKBA) |
| Form Type | 8-K |
| Filed Date | Mar 15, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: AKBA
TL;DR
Akebia's board is shaking up with new directors and exec comp changes.
AI Summary
On March 15, 2024, Akebia Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the filing announced the departure of director John P. Butler and the election of new directors, including Dr. Marc Dunoyer and Ms. Sarah L. Kelly. The report also covers compensatory arrangements for certain officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance expectations.
Risk Assessment
Risk Level: medium — Board and executive changes can indicate internal shifts that may impact future strategy and performance.
Key Players & Entities
- Akebia Therapeutics, Inc. (company) — Registrant
- John P. Butler (person) — Departing Director
- Dr. Marc Dunoyer (person) — Newly Elected Director
- Ms. Sarah L. Kelly (person) — Newly Elected Director
- March 15, 2024 (date) — Date of Report
FAQ
Who has departed from Akebia Therapeutics' board of directors?
John P. Butler has departed from Akebia Therapeutics' board of directors as of March 15, 2024.
Who are the newly elected directors at Akebia Therapeutics?
Dr. Marc Dunoyer and Ms. Sarah L. Kelly have been elected as new directors at Akebia Therapeutics.
What is the primary purpose of this 8-K filing?
This 8-K filing primarily reports on the departure of directors, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
When was this report filed?
This report was filed on March 15, 2024.
What is Akebia Therapeutics' principal executive office address?
Akebia Therapeutics' principal executive offices are located at 245 First Street, Cambridge, Massachusetts, 02142.
Filing Stats: 864 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2024-03-15 16:05:59
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share AKBA The Nasdaq Capital M
Filing Documents
- d650653d8k.htm (8-K) — 24KB
- 0001193125-24-069123.txt ( ) — 140KB
- akba-20240315.xsd (EX-101.SCH) — 3KB
- akba-20240315_lab.xml (EX-101.LAB) — 17KB
- akba-20240315_pre.xml (EX-101.PRE) — 11KB
- d650653d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AKEBIA THERAPEUTICS, INC. Date: March 15, 2024 By: /s/ John P. Butler Name: John P. Butler Title: President and Chief Executive Officer